Leading Companies

Anaveon AG

Anaveon is a late pre-clinical phase biotech developing next generation therapeutic antiobodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer. Anaveon develops a selective interleukin-2 receptor (IL-2 receptor) agonist to fuel a patient’s immune system to respond to tumors. The naturally occurring IL-2 receptor stimulates a type of immune cell called a T-cell to attack tumors. Il-2 is already being used for the treatment of cancer. However, there are side effects and dose limiting toxicities associated with IL-2 therapy. Anaveon`s approach plans to overcome these challenges and the proceeds of the Series A financing will now enable further development of its lead compound, as announced in a press release.

Anaveon AG

Hochbergerstr. 60C
4057 Basel

Bio Technology (Biotech)
Life Science
Country of Origin
Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program